Comparison
Cetilistat vs Semaglutide
Fat-blocker versus hunger-killer: Mechanistic stacking vs. single-agent appetite erasure.
Cetilistat
Gastrointestinal Lipase Inhibitor
Semaglutide
GLP-1 Receptor Agonist
Effectiveness Profile
At a Glance
| Cetilistat | Semaglutide | |
|---|---|---|
| Type | Metabolic Peptide | Metabolic Peptide |
| Legal status | Research | Rx-Only |
| Half-life | Not systemically absorbed — meal-bound activity | ~7 days (155–184 hours) |
| Preferred route | Oral | SubQ |
| Dose frequency | three-times-daily | weekly |
| Beginner dose | 60–80 mg | 0.25–0.5 mg |
| Intermediate dose | 120–120 mg | 0.5–1.7 mg |
| Advanced dose | 120–240 mg | 1.7–2.4 mg |
| Cycle length | 8–16 wks | 12–68 wks |
| Bioavailability | 1% | 89% |
| Time to peak | — | 48h |
| Active duration | 4h | 168h |
| Storage | Room temperature, dry storage in sealed blister | 2–8°C refrigerated; stable ~28 days reconstituted |
| PCT required | No | No |
| Ancillaries required | Yes | No |
| Safe for women | Yes | Yes |
Verdict
Cetilistat wins for meal-targeted fat absorption block, GI safety profile (vs. orlistat), and stacking for modest extra deficit without systemic side effects or rebound. Rapid onset, does not alter appetite or central control, minimal impact on muscle mass if diet is managed.
Semaglutide wins for sheer potency: consistent, double-digit percentage bodyweight reduction across trials, best-in-class appetite suppression, and the ability to induce larger, chronic energy deficits with minimal willpower. Works systemically, produces major sustained loss when diet adherence is otherwise unachievable. Also delivers improvements in glucoregulatory markers for those stacking with GH/slin or running post-blast cleanups.
Pick A or B?
Pick Cetilistat if:
- Small but real caloric deficits are needed on top of existing fat-loss agents
- 'Cheat meal' or refeed damage control protocols are in play
- Orlistat causes unmanageable GI distress but a fat absorption block is still useful
- Stacking with a GLP-1 agonist for additive effect in contest prep or aggressive cuts
- Users want to avoid appetite suppression, muscle loss, or major systemic changes
Pick Semaglutide if:
- Primary goal is major, sustained weight reduction and appetite management is the main bottleneck
- Deep deficits, willpower-free compliance, or chronic 'food noise' suppression are priorities
- High-level or extended cuts require something stronger than any single oral agent
- Cruise dosing for recomposition or post-blast clean-up after heavy AAS/bulking phases
- Proven, vendor-reliable GLP-1 agonists are preferred over GI-targeted blockades